GBB
AI Biomedical R&D Company
Hong Kong
October 18, 2024
"Thick Accumulation, Thin Eruption: GBB's New Product Launch of Intelligent Drug Development Ecosystem Successfully Held Today in Suzhou, Gathering Industry Peers for a Feast of Innovative Technologies"Intelligent Drug Development Ecosystem Empowers the Entire Process of Drug Discovery and Bioprocess Development, from Drug Discovery, Molecular Sequence Generation and Optimization, to Cell Line Development, and Further to Media Development and Optimization, Bringing Revolutionary Changes to Biopharmaceutical Development and Helping Customers Develop Products Faster and Better.
▲GBB Intelligent Drug Development Ecosystem New Product Launch Successfully Concluded
Mr. Liang Guolong, Co-founder and Chairman of Great Bay Bio, said: "We are very pleased to join many biopharmaceutical professionals in Suzhou to discuss the new future of industry development. We have always believed that the power of technology can transform the landscape of biopharmaceutical development.Through an intelligent drug development ecosystem, we bring revolutionary changes to biopharmaceutical development, addressing long-standing issues in the industry such as lengthy drug development cycles, high costs, and low success rates.In the future, Great Bay Bio will continue to uphold technological innovation, collaborate with global partners, and further drive the transformation and development of the biopharmaceutical industry, allowing patients worldwide to benefit from the advancements in technology."
▲ GBB Co-Founder and Chairman Mr. Guolong Liang Delivers a Speech
Dr. Liang Chen, co-founder and CEO of Great Bay Bio, stated:"The intelligent drug development ecosystem is gradually improving with the establishment of GBB's intelligent technology platforms and the implementation of various products, significantly shortening the drug development cycle and increasing product output."
▲GBB Co-founder and CEO Dr. Liang Chen Delivers Technical Speech
In the drug molecule discovery and optimization phase,The AlfaDAX platform has pioneered the simultaneous optimization of three dimensions: humanization, affinity, and drug-likeness, with a drug-likeness prediction accuracy rate reaching approximately 90%.Customers comprehensively evaluate the potential of candidate protein molecules to become developable, safe, and effective drugs through protein structure prediction, hydrophilic/hydrophobic group analysis, positive/negative charge clustering, immunogenicity (humanization), molecular docking, and affinity analysis. Before the candidate protein molecules enter the CMC stage, the AlfaDAX platform helps customers quickly screen and modify candidate molecules, reducing trial-and-error costs and accelerating the new drug development process.
In the cell line construction process, the AlfaCell platform combines AI technology with site-specific integration to enable rapid analysis and precise targeting, accurately inserting the target product gene into stable, high-expression, high-quality, highly active site locations, eliminating the random blind selection traditionally associated with cell line construction.The AlfaCell targeted integration cell line development platform can obtain stable high-yield monoclonal cell lines within 1.5 months. Customer products with IND applications have reached 15g/L. Moreover, the AlfaCell platform excels particularly in addressing bispecific antibody development challenges, with nanobody products reaching 13.1g/L and tetravalent bispecific antibodies achieving 8.3g/L.
In the medium development and optimization process,The catalog media of the AlfaMedX platform have good universality, and the culture results are comparable to or better than those of commercial media.AlfaOPA PlatformUsing AI technology to deeply analyze supernatant data during the cell culture process and calculate influencing parameters of amino acids, vitamins, metal elements, and other component contents.Intelligently optimize the required additives and their amounts in cell culture media to further increase product yield.
In addition, the platform of the intelligent drug development ecosystem can also help customers quickly and effectively screen drug targets, discover new products, and accelerate the rapid entry of products into the clinical stage.
▲GBB Intelligent Drug Development Ecosystem
AlfaCell Transient Transfection Kit
The AlfaCell platform transient transfection kit utilizes site-specific integration technology to achieve "multi-purpose use of a single strain," which can be used for both transient protein sample preparation and stable cell line construction for IND submission. The product quality of transient transfection using the AlfaCell cell line is consistent with that of later-stage process production, significantly reducing product development risks.
▲AlfaCell Transient Transfection Kit
AlfaMedX Catalog Media
The protein expression of AlfaMedX platform catalog media is equivalent to or better than that of commercial media, with a maximum increase of approximately 200%, and exhibits good versatility, suitable for the cultivation of cell lines across different products.
▲AlfaMedX Catalog Media
AlfaNulla Zero-Mistake Weighing System
AlfaNulla Zero-Mistake Weighing System is another remarkable achievement in intelligent and automated products by Great Bay Bio. It completely eliminates errors caused by improper manual operation, significantly reduces the time required for raw material weighing, ensures 100% accuracy in the final results, and effectively cuts labor and material costs.
▲AlfaNulla Zero-Mistake Weighing System
▲Group photo of GBB team
END
Great Bay Bio Intelligent Drug Development Ecosystem Officially Launched
Hong Kong
Oct 18, 2024
Today, the new product launch event hosted by Great Bay Bio (hereinafter referred to as “GBB”) was successfully held in Suzhou, where industry players gathered to celebrate the feast of technological innovation. At the event, GBB announced the official launch of the Intelligent Drug Development Ecosystem. The Intelligent Drug Development Ecosystem empowers the entire process of drug discovery and bioprocess development, from drug discovery, molecular sequence generation and optimization, to cell line development, to culture media development and optimization, etc., giving revolutionary changes to biopharmaceutical development, helping customers develop products faster and better.
▲ Intelligent Drug Development Ecosystem officially launched
Mr. Kingsley Leung, co-founder and chairman of GBB, said: "I am very happy to discuss the new future of the industry with many colleagues in biopharmaceuticals in Suzhou. We always believe that technology's power can change the biopharmaceutical development pattern. Through the Intelligent Drug Development Ecosystem, we have brought revolutionary changes to biopharmaceutical development and solved the problems of long drug development cycles, high costs, and low success rates that have long plagued the industry. In the future, Great Bay Bio will adhere to technological innovation and work with global partners to further promote the transformation and development of the biopharmaceutical industry, so that patients around the world can enjoy the benefits brought by scientific and technological progress."
▲ Mr. Kingsley Leung, Co-founder and Chairman of Great Bay Bio
Dr. Michael Chen, co-founder and CEO of Great Bay Bio, remarked, "The Intelligent Drug Development Ecosystem has evolved alongside the establishment of various intelligent technology platforms at Great Bay Bio and the successful launch of multiple products, gradually progressing from its initial concept to a fully mature system. The Intelligent Drug Development Ecosystem significantly shortens drug development timelines and increases product yield.”
▲ Dr. Michael Chen, Co-founder and CEO of Great Bay Bio
In the drug molecule discovery and optimization part, the AlfaDAX platform pioneeringly synchronizes optimization across the three dimensions of humanization, affinity, and druggability, achieving an approximately 90% accuracy in druggability prediction. Customers comprehensively assess the potential of protein candidates to become developable, safe, and effective drugs through protein structure prediction, affinity/hydrophobic group analysis, positive/negative charge aggregation, immunogenicity (humanization), molecular docking, and affinity analysis. Before the candidate protein molecule enters the CMC stage, the AlfaDAX platform helps customers quickly screen and modify the candidate molecule, reduce the cost of trial and error, and accelerate the process of new drug development.
In the cell line development part, the AlfaCell platform combines AI technology with site-specific integration technology to quickly analyze and precisely locate the target product gene, inserting it into the stable and high-yield “hot spot”, eliminating the random and blind selection process in cell line development. The AlfaCell platform can obtain stable and high-yield monoclonal cell lines within 1.5 months, and the customer products that have been declared for IND have reached 15g/L, and the AlfaCell platform is particularly outstanding in solving the problem of bispecific antibody development, with nanobody products reaching 13.1g/L and quadruple bispecific antibody reaching 8.3g/L.
In the cell culture media development and optimization part, the AlfaMedX culture media have good universality, and the culture results are comparable or better than those of commercial media. The AlfaOPA platform uses AI technology to deeply analyze the supernatant data in the cell culture process, calculate the influencing parameters of amino acids, vitamins, metal elements and other components, and intelligently optimize the added components and amounts required for cell culture media to further improve product yield.
Moreover, the intelligent technology platforms in the ecosystem can help customers quickly and effectively screen drug targets, discover new products, and accelerate the rapid entry of products into clinical stages.
▲ Intelligent Drug Development Ecosystem
AlfaCell - Transient
AlfaCell - Transient Transfection Kit utilizes site-specific integration technology, which can be used both for transient protein sample preparation and for stable cell line development for IND filing. Products produced through transient transfection using AlfaCell cell lines are consistent in quality with those produced during later-stage manufacturing, significantly reducing development risks.
▲ AlfaCell Transient Transfection Kit
AlfaMedX Culture Media
The protein expression of AlfaMedX culture media is comparable to or better than commercial media, with up to a 200% increase. The media demonstrate excellent versatility, making them suitable for cultivating cell lines for various products.
▲ AlfaMedX Culture Media
AlfaNulla Precision Weighing System
The AlfaNulla Precision Weighing System is another intelligent and automated product of GBB. It completely eliminates errors caused by improper manual operation, making the media weighing process intelligent and efficient. The system significantly shortens the raw material weighing time, and the final weighing results are 100% accurate, effectively reducing labor and material costs.
▲ AlfaNulla Presicion Weighing System
▲ GBB team
END